Cingulate Inc. is a biopharmaceutical company that develops product candidates for the treatment of attention-deficit/hyperactivity disorder and anxiety disorders. It has two lead products, CTx-1301 and CTx-1302, in clinical trials for treating ADHD. The company was founded in 2012 and is headquartered in Kansas City, Kansas.